Minnesota 340B revenue driven by hospitals and high-priced drugs, first state report says

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

FDA approves Alvotech and Teva’s SELARSDI for new indications

SELARSDI, a human monoclonal antibody, targets the p40 protein found in interleukin (IL)-12 and IL-23 cytokines – key in immune-mediated diseases. Credit: BlurryMe/Shutterstock. The US

October 23, 2024

Research identifies key factors in initiating tumor dormancy

A new research paper was published in Oncotarget’s Volume 15 on October 11, 2024, entitled “Initiation of tumor dormancy by the lymphovascular embolus.”

October 30, 2024

APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer – Biotech Investments

EQS-News: APONTIS PHARMA AG / Key word(s): Tender Offer APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary

October 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.